In a groundbreaking move, the World Health Organization (WHO) has added the coronavirus vaccine produced by the Chinese company CanSino Biologics to its emergency use list. The vaccine has demonstrated a 92% efficacy in thwarting severe forms of coronavirus infections and a 64% efficacy rate against symptomatic manifestation.
Scientists at CanSino Biologics have leveraged a modified human adenovirus to develop the vaccine. This cutting-edge technology is similar to that used by Johnson & Johnson and AstraZeneca in their vaccine production processes. The vaccine, which comprises of a single component, is specifically approved for people over 18 years of age.
This latest development marks a significant breakthrough in the fight against the pandemic, as it offers yet another potent tool for combating the virus. The CanSino Biologics vaccine is expected to be a game-changer, especially for those who are most vulnerable to the deadly virus. Its inclusion in the WHO emergency use list is expected to provide a much-needed boost to global vaccination efforts.
Leave a Reply